Chronic Migraine

Neurology
11
Pipeline Programs
8
Companies
11
Clinical Trials
2 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
4
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 9 programs with unclassified modality

On Market (4)

Approved therapies currently available

Teva
AMRIXApproved
cyclobenzaprine hydrochloride
Teva
oral2007
Ipsen
DYSPORTApproved
botulinum toxin type a
Ipsen
Acetylcholine Release Inhibitor [EPC]injection2009
Eli Lilly and Company
EMGALITYApproved
galcanezumab-gnlm
Eli Lilly and Company
injection2018
AbbVie
QULIPTAApproved
atogepant
AbbVie
Calcitonin Gene-related Peptide Receptor Antagonist [EPC]oral2021

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
1
1
Emgality 120 MG in 1 ML Prefilled SyringePhase 41 trial
EMGALITY(Galcanezumab)Phase 3Monoclonal Antibody2 trials
Active Trials
NCT04616326Active Not Recruiting312Est. Mar 2027
NCT02836613Completed160Est. Nov 2017
NCT04271202Completed64Est. Nov 2023
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
1
AtogepantPhase 31 trial
Active Trials
NCT06810505Recruiting420Est. Mar 2031
Ipsen
IpsenChina - Tianjin
1 program
1
1
Botulinum toxin type APhase 31 trial
Active Trials
NCT06047444Active Not Recruiting759Est. Dec 2026
Teva
TevaIsrael - Petach Tikva
1 program
1
1
cyclobenzaprine hydrochloridePhase 31 trial
Active Trials
NCT01151787Terminated35Est. Sep 2013
Ionis Pharmaceuticals
1 program
1
IONIS-PKKRxPhase 21 trial
Active Trials
NCT03108469Completed30Est. Apr 2019
Tonix Pharmaceuticals
Tonix PharmaceuticalsBERKELEY HEIGHTS, NJ
1 program
1
TNX-1900Phase 21 trial
Active Trials
NCT05679908Completed88Est. Oct 2023
Salvia BioElectronics
Salvia BioElectronicsNetherlands - Eindhoven
2 programs
PRIMUSN/A1 trial
PRIMUSN/A1 trial
Active Trials
NCT05858801Active Not RecruitingEst. Jan 2026
NCT06450444RecruitingEst. Feb 2028
M&
Merck & Co.RAHWAY, NJ
1 program
Smell Sensitivity in Chronic Migraine: A Case-Control StudyN/A1 trial
Active Trials
NCT01687088Completed100Est. Mar 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Eli Lilly and CompanyEmgality 120 MG in 1 ML Prefilled Syringe
AbbVieAtogepant
IpsenBotulinum toxin type A
Eli Lilly and CompanyGalcanezumab
Tevacyclobenzaprine hydrochloride
Tonix PharmaceuticalsTNX-1900
Ionis PharmaceuticalsIONIS-PKKRx
Eli Lilly and CompanyGalcanezumab
Salvia BioElectronicsPRIMUS
Salvia BioElectronicsPRIMUS
Merck & Co.Smell Sensitivity in Chronic Migraine: A Case-Control Study

Clinical Trials (11)

Total enrollment: 1,968 patients across 11 trials

NCT04271202Eli Lilly and CompanyEmgality 120 MG in 1 ML Prefilled Syringe

Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

Start: Jul 2020Est. completion: Nov 202364 patients
Phase 4Completed
NCT06810505AbbVieAtogepant

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Start: Feb 2025Est. completion: Mar 2031420 patients
Phase 3Recruiting
NCT06047444IpsenBotulinum toxin type A

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Start: Oct 2023Est. completion: Dec 2026759 patients
Phase 3Active Not Recruiting
NCT04616326Eli Lilly and CompanyGalcanezumab

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Start: Nov 2020Est. completion: Mar 2027312 patients
Phase 3Active Not Recruiting
NCT01151787Tevacyclobenzaprine hydrochloride

Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine

Start: Jul 2010Est. completion: Sep 201335 patients
Phase 3Terminated
NCT05679908Tonix PharmaceuticalsTNX-1900

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

Start: Dec 2022Est. completion: Oct 202388 patients
Phase 2Completed
NCT03108469Ionis PharmaceuticalsIONIS-PKKRx

Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine

Start: Aug 2017Est. completion: Apr 201930 patients
Phase 2Completed
NCT02836613Eli Lilly and CompanyGalcanezumab

A Study of Galcanezumab in Healthy Participants.

Start: Jul 2016Est. completion: Nov 2017160 patients
Phase 1Completed
NCT06450444Salvia BioElectronicsPRIMUS

The RECLAIM Study.

Start: Jun 2024Est. completion: Feb 2028
N/ARecruiting
NCT05858801Salvia BioElectronicsPRIMUS

First Evaluation of a Craniofacial Peripheral Nerve Stimulation System in Chronic Migraine

Start: May 2023Est. completion: Jan 2026
N/AActive Not Recruiting
NCT01687088Merck & Co.Smell Sensitivity in Chronic Migraine: A Case-Control Study

Smell Sensitivity in Chronic Migraine: A Case-Control Study

Start: Jul 2011Est. completion: Mar 2012100 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,968 patients
8 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)